

=> d ibib abs ind hitstr 17 1-1

L7 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:60453 HCAPLUS

DOCUMENT NUMBER: 140:128679

TITLE: Preparation of 4-(4-hydroxyphenoxy)benzoyl amino acids and related compounds as novel thyroid receptor ligands

INVENTOR(S): Garg, Neeraj; Gadim, Mahmoud Rahimi; Ericsson, Thomas Anders Wilson; Malm, Lars Johan; Ryono, Denis Evan

PATENT ASSIGNEE(S): Karo Bio AB, Swed.; Bristol-Myers Squibb Company

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007430	A2	20040122	WO 2003-EP7333	20030708
WO 2004007430	A3	20040219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492046	AA	20040122	CA 2003-2492046	20030708
AU 2003250908	A1	20040202	AU 2003-250908	20030708
BR 2003012655	A	20050524	BR 2003-12655	20030708
EP 1537073	A2	20050608	EP 2003-763744	20030708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1668579	A	20050914	CN 2003-816305	20030708
JP 2005538076	T2	20051215	JP 2004-520522	20030708
NO 2005000714	A	20050210	NO 2005-714	20050210
US 2006135614	A1	20060622	US 2005-520902	20051207
PRIORITY APPLN. INFO.:			GB 2002-15978	A 20020710
			WO 2003-EP7333	W 20030708

OTHER SOURCE(S): MARPAT 140:128679

GI



I

- AB The invention relates to novel compds. I [R1 is H, halo, alkyl; R2 is halo, alk(en)(yn)yl, cycloalkenyl, cycloalkoxy, sulfonamido, acyl, etc.; or R2 is H when R4 is alkyl and R1 is halo; R3 is H, alkyl, benzyl, aroyl, or alkanoyl; R4 is halo, cyano, or alkyl; R5 is H, halo, or alkyl; R6, R7 are H, halo, cyano, alkyl, or cycloalkyl (at least one is not H); R8, R9 are H, halo, alkoxy, OH, cyano, or alkyl; R10, R11 are H, halo, aryl, or alkyl; or R10 and R11 may form a ring; R12 is H or alkyl; R13 is carboxylic, phosphonic, or phosphinic acids or esters, sulfonic acid, tetrazole, hydroxamic acid, thiazolidinedione, acylsulfonamide, or other carboxylic acid surrogates], which are thyroid receptor ligands, and to methods for their prepn. and use in preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene. Thus, N-[3,5-dichloro-4-(4-hydroxy-3-isopropyl-5-methylphenoxy)benzoyl]glycine was prepared by saponification of a reaction mixture containing Me [3,5-dichloro-4-(3-isopropyl-4-methoxy-5-methylphenoxy)]benzoate, followed by coupling with glycine Me ester and treatment with BF₃.Me₂S. The product and other compds. of the invention have binding affinities to the thyroid receptor β in the range of IC₅₀ 1.0-100 nM.
- IC ICM C07C235-52
ICS C07C235-34; A61K031-195; A61P005-16
- CC 34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 2, 25
- ST hydroxyphenoxybenzoyl amino acid prepn thyroid receptor ligand;
benzoylglycine hydroxyphenoxy prepn thyroid receptor ligand; acetylglycine hydroxyphenoxyphenyl prepn thyroid receptor ligand
- IT Heart, disease
(arrhythmia; preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as novel thyroid receptor ligands)
- IT Mental and behavioral disorders
(depression; preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as novel thyroid receptor ligands)
- IT Heart, disease
(failure; preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as novel thyroid receptor ligands)
- IT Goiter
(non-toxic; preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as novel thyroid receptor ligands)
- IT Anabolic agents
Anti-inflammatory agents
Antidepressants
Antidiabetic agents
Antihypertensives
Antiobesity agents
Antitumor agents
Anxiolytics
Atherosclerosis
Bone resorption inhibitors
Cognition
Eating disorders
Glaucoma (disease)
Hypercholesterolemia
Hyperthyroidism
Hypolipemic agents
Hypothyroidism
Obesity
Osteoporosis

Skin, disease

Thyroid gland, neoplasm

(preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as novel thyroid receptor ligands)

IT Growth factors, animal

Thyroid hormone receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as novel thyroid receptor ligands)

IT Amino acids, preparation

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as novel thyroid receptor ligands)

IT 94-20-2, Chloropropamide 657-24-9, Metformin

9004-10-8, Insulin, biological studies 10238-21-8,

Glyburide 21187-98-4, Gliclazide 29094-61-9, Glipizide

56180-94-0, Acarbose 72432-03-2, Miglitol

93479-97-1, Glimepiride 97322-87-7, Troglitazone

109229-58-5, Englitazone 111025-46-8, Pioglitazone

122320-73-4, Rosiglitazone 141200-24-0, Darglitazone

430433-17-3, Glipyrizide

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antidiabetic agent; preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as novel thyroid receptor ligands)

IT 219692-18-9P

RL: BYP (Byproduct); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as novel thyroid receptor ligands)

IT 649725-07-5P 649725-08-6P 649725-09-7P

649725-10-0P 649725-11-1P 649725-12-2P

649725-13-3P 649725-14-4P 649725-15-5P

649725-16-6P 649725-17-7P 649725-18-8P

649725-19-9P 649725-20-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as novel thyroid receptor ligands)

IT 100-97-0, Hexamethylenetetramine, reactions 616-34-2,

Glycine methyl ester 1426-58-0, Bis(4-methoxyphenyl)iodonium

tetrafluoroborate 4070-48-8, L-Valine methyl ester

5680-79-5, Glycine methyl ester hydrochloride 6306-52-1,

L-Valine methyl ester hydrochloride 13061-96-6, Methylboronic

acid 19883-41-1, D-Phenylglycine methyl ester hydrochloride

24461-61-8, D-Phenylglycine methyl ester 30525-89-4,

Paraformaldehyde 212688-02-3 219692-15-6

219692-35-0 378786-32-4 525575-63-7

649725-59-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as novel thyroid receptor ligands)

IT 280779-39-7P 649725-21-3P 649725-22-4P

649725-23-5P 649725-24-6P 649725-25-7P

649725-26-8P 649725-27-9P 649725-28-0P

649725-29-1P 649725-30-4P 649725-31-5P

649725-32-6P 649725-33-7P 649725-34-8P

649725-35-9P 649725-36-0P 649725-37-1P

649725-38-2P 649725-39-3P 649725-40-6P
 649725-41-7P 649725-42-8P 649725-43-9P
 649725-44-0P 649725-45-1P 649725-46-2P
 649725-47-3P 649725-48-4P 649725-49-5P
 649725-50-8P 649725-51-9P 649725-52-0P
 649725-53-1P 649725-54-2P 649725-55-3P
 649725-56-4P 649725-57-5P 649725-58-6P
 649725-60-0P 649725-61-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as
 novel thyroid receptor ligands)


IT 94-20-2, Chloropropamide 657-24-9, Metformin
 9004-10-8, Insulin, biological studies 10238-21-8,
 Glyburide 21187-98-4, Glipizide 29094-61-9, Glipizide
 56180-94-0, Acarbose 72432-03-2, Miglitol
 93479-97-1, Glimepiride 97322-87-7, Troglitazone
 109229-58-5, Englitazone 111025-46-8, Pioglitazone
 122320-73-4, Rosiglitazone 141200-24-0, Darglitazone
 430433-17-3, Glipiride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antidiabetic agent; preparation of (hydroxyphenoxy)benzoyl amino acids and
 related compds. as novel thyroid receptor ligands)


RN 94-20-2 HCAPLUS

CN Benzenesulfonamide, 4-chloro-N-[(propylamino)carbonyl]- (9CI) (CA INDEX
 NAME)



RN 657-24-9 HCAPLUS

CN Imidodicarbonimidic diamide, N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 9004-10-8 HCAPLUS

CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 10238-21-8 HCAPLUS

CN Benzamide, 5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 21187-98-4 HCAPLUS

CN Benzenesulfonamide, N-[[[hexahydrocyclopenta[c]pyrrol-2(1H)-yl]amino]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 29094-61-9 HCAPLUS


CN Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino) carbonyl] amino] sulfonyl]p
henyl]ethyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 56180-94-0 HCAPLUS

CN D-Glucose, O-4,6-dideoxy-4-[[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-α-D-glucopyranosyl-(1→4)-O-α-D-glucopyranosyl-(1→4)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 72432-03-2 HCAPLUS

CN 3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-,
(2R,3R,4R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 93479-97-1 HCAPLUS


CN 1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[(trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 97322-87-7 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 109229-58-5 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[3,4-dihydro-2-(phenylmethyl)-2H-1-benzopyran-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 111025-46-8 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


|
Et

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 141200-24-0 HCAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 430433-17-3 HCAPLUS
 CN Glipyrifos (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 219692-18-9P


RL: BYP (Byproduct); RCT (Reactant); PREP (Preparation); RACT (Reactant or

reagent)

(preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as novel thyroid receptor ligands)

RN 219692-18-9 HCAPLUS

CN Benzoic acid, 3,5-dichloro-4-[4-methoxy-3-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




IT 649725-07-5P 649725-08-6P 649725-09-7P
 649725-10-0P 649725-11-1P 649725-12-2P
 649725-13-3P 649725-14-4P 649725-15-5P
 649725-16-6P 649725-17-7P 649725-18-8P
 649725-19-9P 649725-20-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as novel thyroid receptor ligands)


RN 649725-07-5 HCAPLUS

CN Glycine, N-[3,5-dichloro-4-[4-hydroxy-3-methyl-5-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 649725-08-6 HCAPLUS


CN Glycine, N-[4-[3-bromo-4-hydroxy-5-(1-methylethyl)phenoxy]-3,5-dichlorobenzoyl]- (9CI) (CA INDEX NAME)



RN 649725-09-7 HCAPLUS


CN Glycine, N-[4-[2-bromo-4-hydroxy-5-(1-methylethyl)phenoxy]-3,5-

dichlorobenzoyl]- (9CI) (CA INDEX NAME)




RN 649725-10-0 HCAPLUS

CN Glycine, N-[3,5-dichloro-4-[3-chloro-4-hydroxy-5-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)




RN 649725-11-1 HCAPLUS

CN Glycine, N-[3,5-dichloro-4-[3-cyano-4-hydroxy-5-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 649725-12-2 HCAPLUS


CN Glycine, N-[3,5-dichloro-4-[3-fluoro-4-hydroxy-5-(1-methylethyl)phenoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 649725-13-3 HCAPLUS


CN Glycine, N-[3,5-dichloro-4-[4-hydroxy-3-methyl-5-(1-methylethyl)phenoxy]-2-

methylbenzoyl]- (9CI) (CA INDEX NAME)




RN 649725-14-4 HCAPLUS

CN Glycine, N-[3,5-dibromo-4-[4-hydroxy-3-methyl-5-(1-methylethyl)phenoxy]-2-methylbenzoyl]- (9CI) (CA INDEX NAME)



RN 649725-15-5 HCAPLUS


CN Glycine, N-[4-[4-hydroxy-3-methyl-5-(1-methylethyl)phenoxy]-2,3,5-trimethylbenzoyl]- (9CI) (CA INDEX NAME)



RN 649725-16-6 HCAPLUS

CN L-Valine, N-[[3,5-dibromo-4-[3-fluoro-4-hydroxy-5-(1-methylethyl)phenoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 649725-17-7 HCAPLUS

CN Benzeneacetic acid, α -[[[3,5-dibromo-4-[3-chloro-4-hydroxy-5-(1-methylethyl)phenoxy]phenyl]acetyl]amino]-, (α R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 649725-18-8 HCAPLUS

CN L-Valine, N-[[[3,5-dibromo-4-[4-hydroxy-3-methyl-5-(1-methylethyl)phenoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 649725-19-9 HCAPLUS

CN Benzeneacetic acid, α -[[[3,5-dibromo-4-[4-hydroxy-3-methyl-5-(1-methylethyl)phenoxy]phenyl]acetyl]amino]-, (α R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 649725-20-2 HCAPLUS

CN Benzeneacetic acid, α -[[[3,5-dibromo-4-(4-hydroxy-3,5-dimethylphenoxy)phenyl]acetyl]amino]-, (α R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 100-97-0, Hexamethylenetetramine, reactions 616-34-2,
 Glycine methyl ester 1426-58-0, Bis(4-methoxyphenyl)iodonium
 tetrafluoroborate 4070-48-8, L-Valine methyl ester
 5680-79-5, Glycine methyl ester hydrochloride 6306-52-1,
 L-Valine methyl ester hydrochloride 13061-96-6, Methylboronic
 acid 19883-41-1, D-Phenylglycine methyl ester hydrochloride
 24461-61-8, D-Phenylglycine methyl ester 30525-89-4,
 Paraformaldehyde 212688-02-3 219692-15-6
 219692-35-0 378786-32-4 525575-63-7
 649725-59-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as
 novel thyroid receptor ligands)
 RN 100-97-0 HCAPLUS
 CN 1,3,5,7-Tetraazatricyclo[3.3.1.1^{3,7}]decane (9CI) (CA INDEX NAME)




RN 616-34-2 HCAPLUS
 CN Glycine, methyl ester (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 1426-58-0 HCAPLUS
 CN Iodonium, bis(4-methoxyphenyl)-, tetrafluoroborate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 46835-94-3
 CMF C14 H14 I O2




CM 2

CRN 14874-70-5

CMF B F4


CCI CCS



RN 4070-48-8 HCAPLUS


CN L-Valine, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 5680-79-5 HCAPLUS

CN Glycine, methyl ester, hydrochloride (6CI, 8CI, 9CI) (CA INDEX NAME)




● HCl

RN 6306-52-1 HCAPLUS


CN L-Valine, methyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 13061-96-6 HCAPLUS
CN Boronic acid, methyl- (9CI) (CA INDEX NAME)



RN 19883-41-1 HCAPLUS
CN Benzeneacetic acid, α-amino-, methyl ester, hydrochloride,
(αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



● HCl

RN 24461-61-8 HCAPLUS
CN Benzeneacetic acid, α-amino-, methyl ester, (αR)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 30525-89-4 HCAPLUS
CN Paraformaldehyde (9CI) (CA INDEX NAME)

CM 1


CRN 50-00-0

CMF C H2 O

 $\text{H}_2\text{C}=\text{O}$


RN 212688-02-3 HCAPLUS

CN Benzeneacetic acid, 3,5-dibromo-4-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 219692-15-6 HCAPLUS

CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-3-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 219692-35-0 HCAPLUS

CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-3-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 378786-32-4 HCAPLUS

CN Benzoic acid, 3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 525575-63-7 HCAPLUS

CN Benzeneacetic acid, 3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 649725-59-7 HCAPLUS

CN Glycine, N-[3,5-dibromo-4-[4-methoxy-3-(1-methylethyl)phenoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 280779-39-7P 649725-21-3P 649725-22-4P
 649725-23-5P 649725-24-6P 649725-25-7P
 649725-26-8P 649725-27-9P 649725-28-0P
 649725-29-1P 649725-30-4P 649725-31-5P
 649725-32-6P 649725-33-7P 649725-34-8P
 649725-35-9P 649725-36-0P 649725-37-1P
 649725-38-2P 649725-39-3P 649725-40-6P
 649725-41-7P 649725-42-8P 649725-43-9P
 649725-44-0P 649725-45-1P 649725-46-2P
 649725-47-3P 649725-48-4P 649725-49-5P
 649725-50-8P 649725-51-9P 649725-52-0P
 649725-53-1P 649725-54-2P 649725-55-3P
 649725-56-4P 649725-57-5P 649725-58-6P
 649725-60-0P 649725-61-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (hydroxyphenoxy)benzoyl amino acids and related compds. as novel thyroid receptor ligands)


RN 280779-39-7 HCAPLUS

CN Glycine, N-[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-21-3 HCAPLUS

CN Benzoic acid, 4-[3-amino-4-methoxy-5-(1-methylethyl)phenoxy]-3,5-dichloro-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-22-4 HCAPLUS

CN Benzoic acid, 3,5-dichloro-4-[3-iodo-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-23-5 HCAPLUS

CN Benzoic acid, 3,5-dichloro-4-[4-methoxy-3-methyl-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-24-6 HCAPLUS

CN Glycine, N-[3,5-dichloro-4-[4-methoxy-3-methyl-5-(1-methylethyl)phenoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-25-7 HCAPLUS

CN Glycine, N-[4-[3-bromo-4-hydroxy-5-(1-methylethyl)phenoxy]-3,5-dichlorobenzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-26-8 HCAPLUS

CN Glycine, N-[4-[2-bromo-4-methoxy-5-(1-methylethyl)phenoxy]-3,5-dichlorobenzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-27-9 HCAPLUS

CN Benzoic acid, 3,5-dichloro-4-[3-chloro-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-28-0 HCAPLUS

CN Benzoic acid, 3,5-dichloro-4-[3-chloro-4-methoxy-5-(1-methylethyl)phenoxy] -
(9CI) (CA INDEX NAME)




RN 649725-29-1 HCAPLUS

CN Glycine, N-[3,5-dichloro-4-[3-chloro-4-methoxy-5-(1-methylethyl)phenoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-30-4 HCAPLUS

CN Benzoic acid, 3,5-dichloro-4-[3-cyano-4-methoxy-5-(1-methylethyl)phenoxy] -
, methyl ester (9CI) (CA INDEX NAME)




RN 649725-31-5 HCAPLUS

CN Glycine, N-[3,5-dichloro-4-[3-cyano-4-hydroxy-5-(1-methylethyl)phenoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-32-6 HCAPLUS

CN Benzoic acid, 3,5-dichloro-4-[4-methoxy-3-(1-methylethyl)-5-nitrophenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-33-7 HCAPLUS

CN Benzoic acid, 3,5-dichloro-4-[4-methoxy-3-(1-methylethyl)-5-nitrophenoxy]- (9CI) (CA INDEX NAME)




RN 649725-34-8 HCAPLUS

CN Glycine, N-[3,5-dichloro-4-[4-methoxy-3-(1-methylethyl)-5-nitrophenoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-35-9 HCAPLUS

CN Glycine, N-[4-[3-amino-4-methoxy-5-(1-methylethyl)phenoxy]-3,5-dichlorobenzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-36-0 HCAPLUS

CN Glycine, N-[3,5-dichloro-4-[3-fluoro-4-methoxy-5-(1-methylethyl)phenoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-37-1 HCAPLUS

CN Benzoic acid, 4-[3-bromo-4-hydroxy-5-(1-methylethyl)phenoxy]-3,5-dichloro-2-methyl- (9CI) (CA INDEX NAME)




RN 649725-38-2 HCAPLUS

CN Benzoic acid, 4-[3-bromo-4-hydroxy-5-(1-methylethyl)phenoxy]-3,5-dichloro-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-39-3 HCAPLUS

CN Benzoic acid, 3,5-dichloro-4-[4-hydroxy-3-methyl-5-(1-methylethyl)phenoxy]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-40-6 HCAPLUS

CN Benzoic acid, 3,5-dichloro-4-[4-hydroxy-3-methyl-5-(1-methylethyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 649725-41-7 HCAPLUS

CN Glycine, N-[3,5-dichloro-4-[4-hydroxy-3-methyl-5-(1-methylethyl)phenoxy]-2-methylbenzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-42-8 HCAPLUS

CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-3-(1-methylethyl)-5-nitrophenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-43-9 HCAPLUS

CN Benzeneacetic acid, 4-[3-amino-4-methoxy-5-(1-methylethyl)phenoxy]-3,5-dibromo-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-44-0 HCAPLUS

CN Benzeneacetic acid, 3,5-dibromo-4-[3-fluoro-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 649725-45-1 HCAPLUS


CN Benzeneacetic acid, 3,5-dibromo-4-[3-fluoro-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 649725-46-2 HCAPLUS


CN L-Valine, N-[[3,5-dibromo-4-[3-fluoro-4-methoxy-5-(1-methylethyl)phenoxy]phenyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 649725-47-3 HCAPLUS

CN Benzeneacetic acid, 3,5-dibromo-4-[3-chloro-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 649725-48-4 HCAPLUS
 CN Benzeneacetic acid, α -[[[3,5-dibromo-4-[3-chloro-4-methoxy-5-(1-methylethyl)phenoxy]phenyl]acetyl]amino]-, methyl ester, (α R)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.




RN 649725-49-5 HCAPLUS
 CN Benzeneacetic acid, 3,5-dibromo-4-[3-formyl-4-hydroxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 649725-50-8 HCAPLUS
 CN Benzeneacetic acid, 3,5-dibromo-4-[4-hydroxy-3-methyl-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-51-9 HCAPLUS
 CN Benzeneacetic acid, 3,5-dibromo-4-[4-hydroxy-3-methyl-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 649725-52-0 HCAPLUS

CN L-Valine, N-[[3,5-dibromo-4-[4-hydroxy-3-methyl-5-(1-methylethyl)phenoxy]phenyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 649725-53-1 HCAPLUS


CN Benzeneacetic acid, α -[[[3,5-dibromo-4-[4-hydroxy-3-methyl-5-(1-methylethyl)phenoxy]phenyl]acetyl]amino]-, methyl ester, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 649725-54-2 HCAPLUS


CN Benzeneacetic acid, 3,5-dibromo-4-(3-formyl-4-hydroxyphenoxy)-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-55-3 HCAPLUS
 CN Benzeneacetic acid, 3,5-dibromo-4-(4-hydroxy-3-methylphenoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 649725-56-4 HCAPLUS
 CN Benzeneacetic acid, 3,5-dibromo-4-(3-formyl-4-hydroxy-5-methylphenoxy)-, methyl ester (9CI) (CA INDEX NAME)




RN 649725-57-5 HCAPLUS
 CN Benzeneacetic acid, 3,5-dibromo-4-(4-hydroxy-3,5-dimethylphenoxy)- (9CI) (CA INDEX NAME)




RN 649725-58-6 HCAPLUS
 CN Benzeneacetic acid, α -[[[3,5-dibromo-4-(4-hydroxy-3,5-dimethylphenoxy)phenyl]acetyl]amino]-, methyl ester, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 649725-60-0 HCAPLUS

CN Benzoic acid, 3,5-dichloro-4-[4-methoxy-3-methyl-5-(1-methylethyl)phenoxy]-
(9CI) (CA INDEX NAME)



RN 649725-61-1 HCAPLUS

CN Benzeneacetic acid, 3,5-dibromo-4-(4-hydroxyphenoxy)-, methyl ester (9CI)
(CA INDEX NAME)



=> analyze l7 1 ct
L8 ANALYZE L7 1 CT : 27 TERMS

=> d 1-27
L8 ANALYZE L7 1 CT : 27 TERMS

TERM #	# OCC	# DOC	% DOC	CT
1	2	1	100.00	HEART, DISEASE
2	1	1	100.00	AMINO ACIDS, PREPARATION
3	1	1	100.00	ANABOLIC AGENTS
4	1	1	100.00	ANTI-INFLAMMATORY AGENTS
5	1	1	100.00	ANTIDEPRESSANTS
6	1	1	100.00	ANTIDIABETIC AGENTS
7	1	1	100.00	ANTIHYPERTENSIVES
8	1	1	100.00	ANTIOBESITY AGENTS
9	1	1	100.00	ANTITUMOR AGENTS
10	1	1	100.00	ANXIOLYTICS
11	1	1	100.00	ATHEROSCLEROSIS
12	1	1	100.00	BONE RESORPTION INHIBITORS
13	1	1	100.00	COGNITION
14	1	1	100.00	EATING DISORDERS
15	1	1	100.00	GLAUCOMA (DISEASE)
16	1	1	100.00	GOITER
17	1	1	100.00	GROWTH FACTORS, ANIMAL
18	1	1	100.00	HYPERCHOLESTEROLEMIA
19	1	1	100.00	HYPERTHYROIDISM
20	1	1	100.00	HYPOLIPEMIC AGENTS
21	1	1	100.00	HYPOTHYROIDISM
22	1	1	100.00	MENTAL AND BEHAVIORAL DISORDERS
23	1	1	100.00	OBESITY
24	1	1	100.00	OSTEOPOROSIS
25	1	1	100.00	SKIN, DISEASE
26	1	1	100.00	THYROID GLAND, NEOPLASM
27	1	1	100.00	THYROID HORMONE RECEPTORS

***** END OF L8 ***

=>

THIS PAGE LEFT BLANK

=> d his' -

(FILE 'HOME' ENTERED AT 15:51:39 ON 02 SEP 2006)

FILE 'HCAPLUS' ENTERED AT 15:52:01 ON 02 SEP 2006

L1 34 S E2-3
 E GARG NEERAJ/AU
 E GHADIM MAHMOUD RAHIMI/AU
 E ERICSSON THOMAS ANDERS/AU
L2 25 S E1-4
 E MALM LARS JOHAN/AU
L3 4 S E1-3
 E RYONO DENIS EVAN/AU
L4 59 S E1-4
L5 1 S L1 AND L2 AND L3 AND L4
 SELECT RN L5 1-1

FILE 'REGISTRY' ENTERED AT 15:54:39 ON 02 SEP 2006

L6 87 S E1-87

FILE 'HCAPLUS' ENTERED AT 15:55:02 ON 02 SEP 2006

L7 1 S L5 AND L6
L8 ANALYZE L7 1 CT : 27 TERMS

FILE 'HCAPLUS' ENTERED AT 16:35:51 ON 02 SEP 2006

L9 1 S L20 AND L21

THIS PAGE LEFT BLANK